Fig. 2

FOXD3 increases the expression of miR-335 and this increase restrains the chemoresistance of OC cells. A miR-335 expression determined by RT-qPCR in A2780S, IOSE80 and A2780CP cell lines. B miR-335 expression determined by RT-qPCR in miR-335 mimic + CP-treated A2780CP cells and miR-335 inhibitor + CP-treated A2780S cells. C Viability of miR-335 mimic + CP-treated A2780CP cells and miR-335 inhibitor + CP-treated A2780S cells measured by CCK-8 assay. D Colony formation of miR-335 mimic + CP-treated A2780CP cells and miR-335 inhibitor + CP-treated A2780S cells measured by colony formation assay. E Flow cytometric analysis of the apoptosis of miR-335 mimic + CP-treated A2780CP cells and miR-335 inhibitor + CP-treated A2780S cells. F The binding site between the promoter of miR-335 and FOXD3 predicted through the JASPAR website. G Binding of FOXD3 to the promoter of miR-335 determined by dual-luciferase reporter assay. H Enrichment of FOXD3 in the promoter region of miR-335 determined by ChIP assay. I miR-335 expression determined by RT-qPCR in oe-FOXD3-treated A2780CP cells. * p < 0.05, compared with IOSE80 cells, mimic NC + CP-treated A2780CP cells, pGL3-basic, IgG antibody or oe-NC-treated A2780CP cells; # p < 0.05, compared with A2780S cells, inhibitor NC + CP-treated A2780S cells or the pGL3-promoter vector. The experiment was conducted three times independently